Deals

research deal two people shaking hands in lab

Merck opts in on Evaxian's preclinical vaccine candidate

Merck is licensing one of Evaxion’s AI platform-based vaccine candidates, offering the biotech up to $592 million for rights to the preclinical asset.

Gabrielle Masson Sep 25, 2025 7:00am

Biopharma biobucks decline, while upfront deal payments rise

Sep 24, 2025 11:30am

3D Rendering futuristic robot technology development artificial intelligence

Merck inks $349M biobucks deal to apply AI to tricky targets

Sep 23, 2025 7:00am

Angelini signs $550M-plus neuro pact with South Korean biotech

Sep 22, 2025 1:47pm

Pfizer inks $4.9B Metsera buyout to beef up obesity pipeline

Sep 22, 2025 7:47am

Japan biotech inks RNA research pact that includes mRNA compounds

Sep 19, 2025 10:49am